Serum Levels of IL-1 RA Increase with Obesity and Type 2 Diabetes in Relation to Adipose Tissue Dysfunction and are Reduced After Bariatric Surgery in Parallel to Adiposity

References

• Bray GA, Frühbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet. 2016;387:1947–1956. doi:10.1016/S0140-6736(16)00271-3
   PubMed Web of Science ®Google Scholar
• Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376:254–266. doi:10.1056/NEJMra1514009
   PubMed Web of Science ®Google Scholar
• Pillon NJ, Loos RJF, Marshall SM, Zierath JR. Metabolic consequences of obesity and type 2 diabetes: balancing genes and environment for personalized care. Cell. 2021;184:1530–1544. doi:10.1016/j.cell.2021.02.012
   PubMed Web of Science ®Google Scholar
• Unamuno X, Gómez-Ambrosi J, Rodríguez A, Becerril S, Frühbeck G, Catalán V. Adipokine dysregulation and adipose tissue inflammation in human obesity. Eur J Clin Invest. 2018;48:e12997. doi:10.1111/eci.12997
   PubMed Web of Science ®Google Scholar
• Frühbeck G, Gómez Ambrosi J. Rationale for the existence of additional adipostatic hormones. FASEB J. 2001;15:1996–2006. doi:10.1096/fj.00-0829hyp
   PubMed Web of Science ®Google Scholar
• Landecho MF, Tuero C, Valentí V, Bilbao I, de la Higuera M, Frühbeck G. Relevance of leptin and other adipokines in obesity-associated cardiovascular risk. Nutrients. 2019;11:2664. doi:10.3390/nu11112664
   PubMed Web of Science ®Google Scholar
• Kahn CR, Wang G, Lee KY. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J Clin Invest. 2019;129:3990–4000. doi:10.1172/JCI129187
   PubMed Web of Science ®Google Scholar
• Zhao S, Kusminski CM, Scherer PE. Adiponectin, leptin and cardiovascular disorders. Circ Res. 2021;128:136–149. doi:10.1161/CIRCRESAHA.120.314458
   PubMed Web of Science ®Google Scholar
• Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39:1003–1018. doi:10.1016/j.immuni.2013.11.010
   PubMed Web of Science ®Google Scholar
• Shuck ME, Eessalu TE, Tracey DE, Bienkowski MJ. Cloning, heterologous expression and characterization of murine interleukin 1 receptor antagonist protein. Eur J Immunol. 1991;21:2775–2780. doi:10.1002/eji.1830211119
   PubMed Web of Science ®Google Scholar
• Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998;16:756.
   Web of Science ®Google Scholar
• Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest. 1997;99:2930–2940. doi:10.1172/JCI119488
   PubMed Web of Science ®Google Scholar
• Hirsch E, Irikura VM, Paul SM, Hirsh D. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci U S A. 1996;93:11008–11013. doi:10.1073/pnas.93.20.11008
   PubMed Web of Science ®Google Scholar
• Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. 2000;191:313–320. doi:10.1084/jem.191.2.313
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633–652. doi:10.1038/nrd3800
   PubMed Web of Science ®Google Scholar
• Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612–632. doi:10.1038/s41584-019-0277-8
   PubMed Web of Science ®Google Scholar
• Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab. 2002;87:1184–1188. doi:10.1210/jcem.87.3.8351
   PubMed Web of Science ®Google Scholar
• Ghanbari M, Momen Maragheh S, Aghazadeh A, et al. Interleukin-1 in obesity-related low-grade inflammation: from molecular mechanisms to therapeutic strategies. Int Immunopharmacol. 2021;96:107765. doi:10.1016/j.intimp.2021.107765
   PubMed Web of Science ®Google Scholar
• Isoda K, Shiigai M, Ishigami N, et al. Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation. 2003;108:516–518. doi:10.1161/01.CIR.0000085567.18648.21
   PubMed Web of Science ®Google Scholar
• Somm E, Henrichot E, Pernin A, et al. Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes. 2005;54:3503–3509. doi:10.2337/diabetes.54.12.3503
   PubMed Web of Science ®Google Scholar
• Isoda K, Sawada S, Ayaori M, et al. Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice. J Biol Chem. 2005;280:7002–7009. doi:10.1074/jbc.M412220200
   PubMed Web of Science ®Google Scholar
• Somm E, Cettour-Rose P, Asensio C, et al. Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia. 2006;49:387–393. doi:10.1007/s00125-005-0046-x
   PubMed Web of Science ®Google Scholar
• Juge-Aubry CE, Somm E, Giusti V, et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes. 2003;52:1104–1110. doi:10.2337/diabetes.52.5.1104
   PubMed Web of Science ®Google Scholar
• Juge-Aubry CE, Somm E, Chicheportiche R, et al. Regulatory effects of interleukin (IL)-1, interferon-b, and IL-4 on the production of IL-1 receptor antagonist by human adipose tissue. J Clin Endocrinol Metab. 2004;89:2652–2658. doi:10.1210/jc.2003-031219
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Classification and Diagnosis of Diabetes: standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S15–S33. doi:10.2337/dc21-S002
   PubMed Web of Science ®Google Scholar
• Gómez-Ambrosi J, González-Crespo I, Catalán V, et al. Clinical usefulness of abdominal bioimpedance (ViScan) in the determination of visceral fat and its application in the diagnosis and management of obesity and its comorbidities. Clin Nutr. 2018;37:580–589. doi:10.1016/j.clnu.2017.01.010
   PubMed Web of Science ®Google Scholar
• Gómez-Ambrosi J, Silva C, Galofré JC, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes. 2012;36:286–294. doi:10.1038/ijo.2011.100
   PubMed Web of Science ®Google Scholar
• Amato MC, Giordano C, Galia M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33:920–922. doi:10.2337/dc09-1825
   PubMed Web of Science ®Google Scholar
• Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95:3347–3351. doi:10.1210/jc.2010-0288
   PubMed Web of Science ®Google Scholar
• Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–1362. doi:10.1002/hep.510300604
   PubMed Web of Science ®Google Scholar
• Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. doi:10.1186/1471-230X-6-33
   PubMed Web of Science ®Google Scholar
• Frühbeck G, Catalán V, Rodríguez A, et al. Normalization of adiponectin concentrations by leptin replacement in ob/ob mice is accompanied by reductions in systemic oxidative stress and inflammation. Sci Rep. 2017;7:2752. doi:10.1038/s41598-017-02848-0
   PubMed Web of Science ®Google Scholar
• Catalán V, Gómez-Ambrosi J, Rotellar F, et al. Validation of endogenous control genes in human adipose tissue: relevance to obesity and obesity-associated type 2 diabetes mellitus. Horm Metab Res. 2007;39:495–500. doi:10.1055/s-2007-982502
   PubMed Web of Science ®Google Scholar
• Cartier A, Bergeron J, Poirier P, et al. Increased plasma interleukin-1 receptor antagonist levels in men with visceral obesity. Ann Med. 2009;41:471–478. doi:10.1080/07853890903022801
   PubMed Web of Science ®Google Scholar
• Hofso D, Ueland T, Hager H, et al. Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. Eur J Endocrinol. 2009;161:451–458. doi:10.1530/EJE-09-0421
   PubMed Web of Science ®Google Scholar
• Carstensen M, Herder C, Kivimaki M, et al. Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: whitehall II prospective cohort study. Diabetes. 2010;59:1222–1227. doi:10.2337/db09-1199
   PubMed Web of Science ®Google Scholar
• Luotola K, Pietila A, Zeller T, et al. Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. J Intern Med. 2011;269:322–332. doi:10.1111/j.1365-2796.2010.02294.x
   PubMed Web of Science ®Google Scholar
• Ballak DB, Stienstra R, Tack CJ, Dinarello CA, van Diepen JA. IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance. Cytokine. 2015;75:280–290. doi:10.1016/j.cyto.2015.05.005
   PubMed Web of Science ®Google Scholar
• Fizelova M, Jauhiainen R, Kangas AJ, et al. Differential associations of inflammatory markers with insulin sensitivity and secretion: the prospective METSIM study. J Clin Endocrinol Metab. 2017;102:3600–3609. doi:10.1210/jc.2017-01057
   PubMed Web of Science ®Google Scholar
• Saltevo J, Vanhala M, Kautiainen H, Kumpusalo E, Laakso M. Association of C-reactive protein, interleukin-1 receptor antagonist and adiponectin with the metabolic syndrome. Mediators Inflamm. 2007;2007:93573. doi:10.1155/2007/93573
   PubMed Web of Science ®Google Scholar
• Franck N, Maris M, Nalbandian S, et al. Knock-down of IL-1Ra in obese mice decreases liver inflammation and improves insulin sensitivity. PLoS One. 2014;9:e107487. doi:10.1371/journal.pone.0107487
   PubMed Web of Science ®Google Scholar
• Herder C, Brunner EJ, Rathmann W, et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care. 2009;32:421–423. doi:10.2337/dc08-1161
   PubMed Web of Science ®Google Scholar
• Grossmann V, Schmitt VH, Zeller T, et al. Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care. 2015;38:1356–1364. doi:10.2337/dc14-3008
   PubMed Web of Science ®Google Scholar
• Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517–1526. doi:10.1056/NEJMoa065213
   PubMed Web of Science ®Google Scholar
• Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care. 2009;32:1663–1668. doi:10.2337/dc09-0533
   PubMed Web of Science ®Google Scholar
• Black MH, Shu YH, Wu J, et al. Longitudinal increases in adiposity contribute to worsening adipokine profile over time in Mexican Americans. Obesity. 2018;26:703–712. doi:10.1002/oby.22128
   PubMed Web of Science ®Google Scholar
• Pihlajamäki J, Kuulasmaa T, Kaminska D, et al. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol. 2012;56:663–670. doi:10.1016/j.jhep.2011.10.005
   PubMed Web of Science ®Google Scholar
• Negrin KA, Roth Flach RJ, DiStefano MT, et al. IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. PLoS One. 2014;9:e107265. doi:10.1371/journal.pone.0107265
   PubMed Web of Science ®Google Scholar
• Carruthers NJ, Strieder-Barboza C, Caruso JA, et al. The human type 2 diabetes-specific visceral adipose tissue proteome and transcriptome in obesity. Sci Rep. 2021;11:17394. doi:10.1038/s41598-021-96995-0
   PubMed Web of Science ®Google Scholar
• Frühbeck G, Catalán V, Rodríguez A, Gómez-Ambrosi J. Adiponectin-leptin ratio: a promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte. 2018;7:57–62. doi:10.1080/21623945.2017.1402151
   PubMed Web of Science ®Google Scholar
• Frühbeck G, Catalán V, Rodríguez A, et al. Adiponectin-leptin ratio is a functional biomarker of adipose tissue inflammation. Nutrients. 2019;11:454. doi:10.3390/nu11020454
   PubMed Web of Science ®Google Scholar
• Strand R, Kullberg J, Ahlstrom H, Lind L. Relationships between plasma levels and six proinflammatory interleukins and body composition using a new magnetic resonance imaging voxel-based technique. Cytokine: X. 2021;3:100050. doi:10.1016/j.cytox.2020.100050
   PubMedGoogle Scholar
• Moschen AR, Molnar C, Enrich B, Geiger S, Ebenbichler CF, Tilg H. Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol Med. 2011;17:840–845. doi:10.2119/molmed.2010.00108
   PubMed Web of Science ®Google Scholar
• Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 2004;323:630–635. doi:10.1016/j.bbrc.2004.08.145
   PubMed Web of Science ®Google Scholar
• Lancha A, Rodríguez A, Catalán V, et al. Osteopontin deletion prevents the development of obesity and hepatic steatosis via impaired adipose tissue matrix remodeling and reduced inflammation and fibrosis in adipose tissue and liver in mice. PLoS One. 2014;9:e98398. doi:10.1371/journal.pone.0098398
   PubMed Web of Science ®Google Scholar
• Ahonen T, Vanhala M, Kautiainen H, Kumpusalo E, Saltevo J. Sex differences in the association of adiponectin and low-grade inflammation with changes in the body mass index from youth to middle age. Gend Med. 2012;9:1–8. doi:10.1016/j.genm.2012.01.002
   PubMedGoogle Scholar
• Jonasson L, Guldbrand H, Lundberg AK, Nystrom FH. Advice to follow a low-carbohydrate diet has a favourable impact on low-grade inflammation in type 2 diabetes compared with advice to follow a low-fat diet. Ann Med. 2014;46:182–187. doi:10.3109/07853890.2014.894286
   PubMed Web of Science ®Google Scholar
• de Mello VD, Kolehmainen M, Schwab U, et al. Effect of weight loss on cytokine messenger RNA expression in peripheral blood mononuclear cells of obese subjects with the metabolic syndrome. Metabolism. 2008;57:192–199. doi:10.1016/j.metabol.2007.08.024
   PubMed Web of Science ®Google Scholar
• Siklova-Vitkova M, Klimcakova E, Polak J, et al. Adipose tissue secretion and expression of adipocyte-produced and stromavascular fraction-produced adipokines vary during multiple phases of weight-reducing dietary intervention in obese women. J Clin Endocrinol Metab. 2012;97:E1176–1181. doi:10.1210/jc.2011-2380
   PubMed Web of Science ®Google Scholar
• Brethauer SA, Heneghan HM, Eldar S, et al. Early effects of gastric bypass on endothelial function, inflammation, and cardiovascular risk in obese patients. Surg Endosc. 2011;25:2650–2659. doi:10.1007/s00464-011-1620-6
   PubMed Web of Science ®Google Scholar
• Feng X, Guan D, Auen T, et al. IL1R1 is required for celastrol’s leptin-sensitization and antiobesity effects. Nat Med. 2019;25:575–582. doi:10.1038/s41591-019-0358-x
   PubMed Web of Science ®Google Scholar
• Frühbeck G, Catalán V, Rodríguez A, et al. Involvement of the leptin-adiponectin axis in inflammation and oxidative stress in the metabolic syndrome. Sci Rep. 2017;7:6619. doi:10.1038/s41598-017-06997-0
   PubMed Web of Science ®Google Scholar
• Wahab F, Santos-Junior NN, de Almeida Rodrigues RP, Costa LHA, Catalao CHR, Rocha MJA. Interleukin-1 receptor antagonist decreases hypothalamic oxidative stress during experimental sepsis. Mol Neurobiol. 2016;53:3992–3998. doi:10.1007/s12035-015-9338-4
   PubMed Web of Science ®Google Scholar
• Choromanska B, Mysliwiec P, Luba M, et al. Bariatric surgery normalizes protein glycoxidation and nitrosative stress in morbidly obese patients. Antioxidants. 2020;9:1087. doi:10.3390/antiox9111087
   Web of Science ®Google Scholar
• Interleukin 1 Genetics C. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2015;3:243–253. doi:10.1016/S2213-8587(15)00034-0
   PubMed Web of Science ®Google Scholar